Endometritis: why chronic symptoms get dismissed as ‘normal

Chronic endometritis lingers in the uterine lining with few dramatic signs, so many patients hear that their bleeding patterns, pelvic twinges, or repeated losses fall within normal range. Recent 2025 reviews confirm the condition remains treatable once identified, yet standard office visits rarely catch it. The gap between subtle symptoms and missed diagnosis now drives fertility patients to ask for targeted testing.

Understated symptoms hide inflammation

Most women report irregular spotting or lighter flow rather than sharp pain. These changes rarely trigger extra workups because they resemble ordinary cycle shifts. Yan et al. noted that the lack of distinctive features keeps chronic endometritis off clinicians’ immediate radar.

Some patients also describe mild backache or post-intercourse discomfort without fever. Because these complaints appear after months of trying to conceive, doctors often attribute them to stress or prior losses. The pattern repeats across forums where women recount being reassured that nothing looks wrong on basic ultrasound.

Without outward markers, the inflammation continues unchecked. Pregnancy rates drop when plasma cells remain in the stroma, yet the absence of acute illness keeps the condition invisible on routine charts.

Prevalence rises with fertility struggles

Studies place chronic endometritis in 2.8 to 39 percent of women facing infertility. Rates climb to 60 percent or higher among those with repeated implantation failure or recurrent miscarriage. The numbers suggest the condition travels with unexplained loss far more often than office notes record.

Patients who receive repeated “everything looks normal” results frequently carry the bacteria that fuel low-grade inflammation. Moreno et al. documented this clinical silence in 2018, and the pattern persists in 2025 data. Fertility clinics now track the overlap more closely, though community hospitals lag.

Each additional loss raises the statistical likelihood that chronic endometritis sits behind the outcome. The data shift the conversation from vague reassurance toward concrete biopsy requests.

Standard tests miss plasma cells

Ultrasound and basic cultures do not detect endometrial plasma cells. CD138 immunohistochemistry on biopsy tissue remains the accepted standard for confirming chronic endometritis. Labs count cells per high-power field, with five or more meeting most diagnostic thresholds.

Without the stain, tissue appears unremarkable under routine review. Patients leave appointments with clean reports while the underlying inflammation persists. Gao et al. identified prolonged menstruation and intermenstrual bleeding as signals that should prompt the specific test.

Fertility specialists increasingly list CD138 when patients present two or more failed transfers. The protocol still requires explicit request in many general practices where the assay sits outside standing orders.

Patients share stories online

Instagram reels from 2025 show women holding printed biopsy orders after multiple miscarriages. They describe cycles that seemed textbook yet yielded positive CD138 results. The posts urge others to ask for immunohistochemistry rather than accept repeated normal labels.

Reddit threads in loss communities echo the same timeline. Users recount bleeding changes dismissed as stress until a specialist ordered the stain. Several report antibiotic clearance followed by successful pregnancies after prior unexplained failures.

These accounts circulate alongside 2025 research summaries, turning individual frustration into collective pressure on providers. The conversation centers on documentation rather than confrontation.

Advocacy pushes for explicit requests

Patient groups now distribute checklists that include CD138 alongside standard fertility panels. The lists appear after clinic visits where symptoms receive the “normal” tag. The goal is to shorten the interval between first complaint and targeted sampling.

Social posts emphasize that antibiotics resolve most cases once plasma cells are confirmed. The message reaches women who have already cycled through multiple specialists without answers. The shift mirrors earlier campaigns around endometriosis but focuses on infection rather than tissue growth.

Clinics that adopt the protocol report faster turnaround from complaint to treatment. The change stems from patient persistence rather than new mandates.

Recent literature reinforces testing gaps

The June 2025 Frontiers in Endocrinology review states that chronic endometritis is frequently overlooked because symptoms lack clear definition. Authors call for broader consideration of biopsy in recurrent pregnancy loss workups. The paper synthesizes earlier prevalence figures with current diagnostic limits.

No sweeping U.S. guideline update has followed yet, though individual practices adjust protocols. The review notes that untreated cases correlate with lower implantation rates even when other markers appear favorable.

Researchers flag the absence of standardized screening as the main barrier. Until criteria expand, the onus stays on patients to request the specific stain.

Antibiotic treatment changes outcomes

Once diagnosed, a course of targeted antibiotics clears plasma cells in most patients. Follow-up biopsy confirms resolution before the next transfer attempt. Success rates improve when inflammation is removed from the equation.

Clinics that retest after treatment document higher ongoing pregnancy numbers compared with untreated cohorts. The difference appears most clearly in patients previously labeled unexplained. The data support earlier testing rather than extended observation.

Side effects remain minimal for the short regimens used. The main obstacle continues to be reaching the diagnosis in the first place.

Insurance and access vary

Coverage for CD138 staining differs by plan and region. Some fertility centers absorb the cost within bundled testing, while others bill separately. Patients outside major centers often pay out of pocket for the add-on stain.

Rural practices report less familiarity with the assay, lengthening referral chains. Advocacy groups compile state-by-state lists of labs that perform the immunohistochemistry routinely. The patchwork leaves timing unpredictable for those already navigating loss.

Telehealth second opinions have shortened the wait in some cases by connecting patients with specialists who order the test directly.

Next steps focus on documentation

Women tracking subtle bleeding shifts now keep symptom logs before appointments. The records help justify biopsy requests when clinicians default to reassurance. Several clinics have added chronic endometritis prompts to intake forms after patient feedback.

Future guidelines may standardize CD138 thresholds and timing, reducing reliance on individual advocacy. Until then, the combination of 2025 research and community discussion keeps the test on the table for those with recurrent issues.

Clearer testing shortens the wait

Chronic endometritis stays hidden when symptoms blend into ordinary cycles, yet the 2025 evidence shows that a single targeted biopsy can redirect care. Patients who reach diagnosis move from repeated loss to treated cycles with measurable gains. The pattern points toward routine consideration of CD138 in unexplained fertility cases rather than continued normalization of vague complaints.